The use of glucocorticoids in marmoset wasting syndrome

Pete Otovic, Shanequa Smith, Eric Hutchinson

Research output: Contribution to journalArticle

Abstract

Background: Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation. Method: Eleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks. Results: The marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy. Conclusions: Glucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalJournal of Medical Primatology
Volume44
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Wasting Syndrome
wasting syndrome
Callithrix
Callitrichidae
glucocorticoids
Glucocorticoids
Budesonide
adverse effects
prednisone
therapeutics
inflammatory bowel disease
Felidae
Prednisone
Inflammatory Bowel Diseases
gastrointestinal system
Intestines
albumins
morbidity
Gastrointestinal Tract
Albumins

Keywords

  • Callitrichid
  • Corticosteroids
  • Inflammatory bowel disease
  • Monkey

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

The use of glucocorticoids in marmoset wasting syndrome. / Otovic, Pete; Smith, Shanequa; Hutchinson, Eric.

In: Journal of Medical Primatology, Vol. 44, No. 2, 01.04.2015, p. 53-59.

Research output: Contribution to journalArticle

Otovic, Pete ; Smith, Shanequa ; Hutchinson, Eric. / The use of glucocorticoids in marmoset wasting syndrome. In: Journal of Medical Primatology. 2015 ; Vol. 44, No. 2. pp. 53-59.
@article{087221a727df476494c305cc0d820fb6,
title = "The use of glucocorticoids in marmoset wasting syndrome",
abstract = "Background: Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation. Method: Eleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks. Results: The marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy. Conclusions: Glucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.",
keywords = "Callitrichid, Corticosteroids, Inflammatory bowel disease, Monkey",
author = "Pete Otovic and Shanequa Smith and Eric Hutchinson",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/jmp.12159",
language = "English (US)",
volume = "44",
pages = "53--59",
journal = "Journal of Medical Primatology",
issn = "0047-2565",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - The use of glucocorticoids in marmoset wasting syndrome

AU - Otovic, Pete

AU - Smith, Shanequa

AU - Hutchinson, Eric

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation. Method: Eleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks. Results: The marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy. Conclusions: Glucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.

AB - Background: Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation. Method: Eleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks. Results: The marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy. Conclusions: Glucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.

KW - Callitrichid

KW - Corticosteroids

KW - Inflammatory bowel disease

KW - Monkey

UR - http://www.scopus.com/inward/record.url?scp=84924588455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924588455&partnerID=8YFLogxK

U2 - 10.1111/jmp.12159

DO - 10.1111/jmp.12159

M3 - Article

C2 - 25614344

AN - SCOPUS:84924588455

VL - 44

SP - 53

EP - 59

JO - Journal of Medical Primatology

JF - Journal of Medical Primatology

SN - 0047-2565

IS - 2

ER -